Tenaya Therapeutics, Inc.
TNYA
$0.4912
$0.03066.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -30.50% | -18.75% | -5.25% | 7.26% | -2.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.61% | -13.61% | -12.20% | 0.12% | -8.98% |
| Operating Income | 21.61% | 13.61% | 12.20% | -0.12% | 8.98% |
| Income Before Tax | 20.37% | 12.04% | 11.54% | -1.55% | 10.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.37% | 12.04% | 11.54% | -1.55% | 10.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.37% | 12.04% | 11.54% | -1.55% | 10.68% |
| EBIT | 21.61% | 13.61% | 12.20% | -0.12% | 8.98% |
| EBITDA | 22.90% | 14.37% | 12.79% | -0.04% | 9.77% |
| EPS Basic | 31.71% | 24.53% | 24.24% | 8.34% | 33.40% |
| Normalized Basic EPS | 31.72% | 24.55% | 24.25% | 8.36% | 33.39% |
| EPS Diluted | 31.71% | 23.90% | 24.24% | 8.34% | 33.40% |
| Normalized Diluted EPS | 31.72% | 24.55% | 24.25% | 8.36% | 33.39% |
| Average Basic Shares Outstanding | 16.61% | 16.55% | 16.77% | 10.79% | 34.11% |
| Average Diluted Shares Outstanding | 16.61% | 16.55% | 16.77% | 10.79% | 34.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |